Trials / Completed
CompletedNCT00624780
Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder
Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 615 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | Pregabalin 150-300 mg given twice a day |
| DRUG | Lorazepam | Lorazepam 3-4 mg given twice a day |
| DRUG | Pregabalin | Pregabalin 450-600 mg given twice a day |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2008-02-27
- Last updated
- 2021-01-28
- Results posted
- 2013-04-19
Locations
57 sites across 16 countries: Argentina, Austria, Costa Rica, Croatia, Czechia, Finland, Greece, India, Indonesia, Lithuania, Mexico, Russia, Serbia, Slovenia, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00624780. Inclusion in this directory is not an endorsement.